AGLEPRISTONE ASSOCIATED WITH OVARIOHISTERECTOMY IN THE TREATMENT OF HYPERPLASIA MAMMARY IN A CAT
DOI:
https://doi.org/10.26605/medvet-v17n4-5542Keywords:
Fibroepithelial hyperplasia; feline; mammary gland; Progesterone; antiprogestationalAbstract
Fibroepithelial hyperplasia, also known as Feline Mammary Hyperplasia (HMF), is characterized by rapid hypertrophy and hyperplasia of the stroma and ductal epithelium of the mammary glands. It corresponds to 20% of mammary nodules and occurs more frequently in felines, females and young people. In view of the high HMF casuistry and lack of standardization of therapeutic protocols, this study aimed to report a case of therapeutic success of HMF in a seven-month-old mongrel cat (SRD), using the ovariohysterectomy (OH) procedure associated to a progesterone antagonist drug, in order to contribute to clarifying the clinical signs, diagnosis and treatment of this condition. The patient is a cat, mixed breed, seven months old and 2.9 kg of live weight, which presented an increase in the volume of the mammary glands one week after the first estrous cycle. History of mating and contraceptive use was denied. All mammary glands were asymmetrically hyperplastic, purple in color, firm consistency, alopecic, with a diameter ranging from 2.5 cm to 4 cm, absence of adhesions and presence of ulcers in the M4 right and left inguinal glands, with painful sensitivity to palpation. The cat was diagnosed with HMF through clinical signs, history and cytopathology. The therapeutic protocol consisted of OH associated with the use of Aglepristone. It should be noted that this protocol is a good option when the owner is not interested in the animal's reproduction, offering fast and effective results with reduced chances of recurrence.Downloads
References
Allen, H.L. Feline mammary hypertrophy. Veterinary Pathology, 10(6): 501-508, 1973.
Burrow, R.; Wawra, E.; Pinchbeck, G.; Senior, M.; Dugdale, A. Prospective evaluation of postoperative pain in cats undergoing ovariohysterectomy by a midline or flank approach. Veterinary Record, 158(19): 657-660, 2006.
Coe, R.J.; Grint, N.J.; Tivers, M.S., Hotston Moore, A.; Holt, P.E. Comparison of flank and midline approaches to the ovariohysterectomy of cats. The Veterinary record, 159(10): 309-313, 2006.
Dyce, K.M.; Sack, W.O.; Wensing, C.J.G. Tegumento comum. In: Tratado de anatomia veterinária. 2ª ed. Rio de Janeiro: Guanabara -Koogan, 1997. 872 p.
Filgueira, K.D.; Reis, P.F.C.; Paula, V.V. Hiperplasia mamária felina: sucesso terapêutico com o uso do aglepristone. Ciência Animal Brasileira, 9(4): 1010-1016, 2008.
Gaviria, E.F.B.; Bonilla, D.E.; Gómez, A.L. Hiperplasia fibroepitelial mamaria felina: reporte de un caso. CES Medicina Veterinaria y Zootecnia, 5(1): 70-76, 2010.
Gorlinger, L.S.; Kooistra, H.S.; Broek, V.D.; Okkens, A.C. Treatment of fibroadenomatous hyperplasia in cats with aglepristone. Journal of Veterinary Internal Medicine, 16(6): 710-713, 2002.
Gudermuth, D.F.; Newton, L.; Daels, P.; Concannon, P. Incidence of spontaneous ovulation in young, group-housed cats based on serum and fecal concentrations of progesterone. Journal of Reproduction and Fertility Supplement, 51(1): 177–184, 1997.
Hayden, D.W.; Barnes, D.M.; Johnson, K.H. Morphologic changes in the mammary gland of megestrol acetate-treated and untreated cats: a retrospective study. Veterinary Pathology, 26(2): 104-113, 1989.
Hinton, M.; Gaskell, C.J. Non-neoplastic memmary hypertrophy in the cat associated either with pregnancy or with oral progestagen therapy. Veterinary Record, 100(14): 277-80, 1977.
Jurka, P.; Max, A. Treatment of fibroadenomatosis in 14 cats with aglepristone - changes in blood parameters and follow-up. Veterinary Record, 165(22): 657-60, 2009.
Leidinger, E.; Hooijberg, E.; Sick, K.; Reinelt, B.; Kirtz, G. Fibroepithelial hyperplasia in an entire male cat: cytologic and histopathological features. Tierärztliche Praxis Ausgabe K: Kleintiere/Heimtiere, 39(3): 198-202, 2011.
Little, S. Feline reproduction: problems and clinical challenges. Journal of Feline Medicine and Surgery, 13(7): 508-515, 2011.
Loretti, A.P.; Ilha, M.R.; Ordás, J.; Martin, D.L.M. Clinical, pathological and immunohistochemical study of feline mammary fibroepithelial hyperplasia following a single injection of depotmedroxyprogesterone acetate. Journal of Feline Medicine Surgery, 7(1): 43-52, 2005.
Marino, G.; Pugliese, M.; Pecchia, F.; Garufi, G.; Lupo, V.; Giorgio, S.D.; Sfacteria, A. Conservative treatments for feline fibroadenomatous changes of the mammary gland. Open Veterinary Journal, 11(4): 680-685, 2021.
Melo, E.H.M.; Câmara, D.R.; Notomi, M.K.; Jabour, F.F.; Garrido, R.A.; Nogueira, A.C.J.; Junior, J.C.S.; Souza, F.W.D. Effectiveness of ovariohysterectomy on feline mammary fibroepithelial hyperplasia treatment. Journal of Feline Medicine and Surgery, 23(4): 351-356, 2021.
Payan-Carreira, R. Feline mammary fibroepithelial hyperplasia: a clinical approach. In: Insights from veterinary medicine e-book. London: IntechOpen, 2013. 291p.
Pantoja, A.R.; Bastos, M.S.; João, C.F. Hiperplasia mamária felina. Ciência Animal, 27(3): 89-98, 2023.
Seberino, G.B.; Ortiz, B.C.; Matte, K.L.; Secchi, P.; Gomes, V.R.; Pozzatti, D.; Figueiredo, K.G. Hiperplasia mamaria felina: relato de caso. PUBVET, 15(1): 1-4. 2021.
Teixeira, J.B.D.C.; Oliveira, C.F.; Guedes, P.E.B.; Carlos, R.C.A. Hiperplasia mamária felina: por que é tão comum no Brasil? Research, Society and Development, 10(5): 1-11, 2021.
Wehrend, A.; Hospes, R.; Gruber, A.D. Treatment of feline mammary fibroadenomatous hyperplasia with a progesterone-antagonist. Veterinary Record, 148(11): 346-7, 2001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Andressa Lima Canedo, Sheila Santana de Mello, Alessandra Aparecida Medeiros Ronchi, Lorena Poliana Rodrigues Gonçalves, Guilherme Nascimento Cunha, Maxsuel Assunção Carvalho, Breno Almeida Wanderley
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
A Revista de Medicina Veterinária permite que o autor retenha os direitos de publicação sem restrições, utilizando para tal a licença Creative Commons CC BY-NC-SA 4.0.
De acordo com os termos seguintes:
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
NãoComercial — Você não pode usar o material para fins comerciais.
CompartilhaIgual — Se você remixar, transformar, ou criar a partir do material, tem de distribuir as suas contribuições sob a mesma licença que o original.
Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
